In a regulatory filing, Alkermes ( ALKS ) disclosed that on December 21, 2022, the company received an interim award in its arbitration proceedings with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson ( JNJ ), in respect of Janssen's partial termination in the United States of two license agreements with the company. "In the Interim Award, the arbitral tribunal agreed with Alkermes' position that, while Janssen may terminate the agreements, it may not continue to sell Products developed during the term of the agreements without paying royalties pursuant to the terms of the respective agreements.